Having demonstrated that the ERCC1 (220-297) peptide can destabilise over-expressed levels of ERCC1 and XPF, we next investigated whether it was also able to reduce endogenous levels of both proteins and so inhibit NER and enhance the sensitivity of cancer cells to DNA damaging agents. Here, ERCC1 is linked to cancer.